KR20230061349A - Smarca2 및/또는 smarca4 저하제로서 6-치환된 피리다진 화합물 - Google Patents

Smarca2 및/또는 smarca4 저하제로서 6-치환된 피리다진 화합물 Download PDF

Info

Publication number
KR20230061349A
KR20230061349A KR1020237005345A KR20237005345A KR20230061349A KR 20230061349 A KR20230061349 A KR 20230061349A KR 1020237005345 A KR1020237005345 A KR 1020237005345A KR 20237005345 A KR20237005345 A KR 20237005345A KR 20230061349 A KR20230061349 A KR 20230061349A
Authority
KR
South Korea
Prior art keywords
cancer
alkyl
carcinoma
compound
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237005345A
Other languages
English (en)
Korean (ko)
Inventor
찬드라세카르 아비네니
수잔타 사마이다르
빌라쉬 쿠일라
수벤두 무케르지
수라즈 타티야사헵 고어
Original Assignee
오리진 온콜로지 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오리진 온콜로지 리미티드 filed Critical 오리진 온콜로지 리미티드
Publication of KR20230061349A publication Critical patent/KR20230061349A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020237005345A 2020-08-04 2021-08-03 Smarca2 및/또는 smarca4 저하제로서 6-치환된 피리다진 화합물 Pending KR20230061349A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN202041033326 2020-08-04
IN202041033326 2020-08-04
PCT/IB2021/057089 WO2022029617A1 (en) 2020-08-04 2021-08-03 6-substituted pyridazine compounds as smarca2 and/or smarca4 degraders

Publications (1)

Publication Number Publication Date
KR20230061349A true KR20230061349A (ko) 2023-05-08

Family

ID=80117730

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237005345A Pending KR20230061349A (ko) 2020-08-04 2021-08-03 Smarca2 및/또는 smarca4 저하제로서 6-치환된 피리다진 화합물

Country Status (11)

Country Link
US (1) US12570650B2 (https=)
EP (1) EP4192835A4 (https=)
JP (1) JP2023536504A (https=)
KR (1) KR20230061349A (https=)
CN (1) CN116529250A (https=)
AU (1) AU2021320052A1 (https=)
BR (1) BR112023002089A2 (https=)
CA (1) CA3188024A1 (https=)
IL (1) IL300387A (https=)
MX (1) MX2023001445A (https=)
WO (1) WO2022029617A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019140380A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2020010227A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2020251972A1 (en) 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
WO2021133917A1 (en) 2019-12-23 2021-07-01 Kymera Therapeutics, Inc. Smarca inhibitors and uses thereof
BR112022012410A2 (pt) 2019-12-23 2022-08-30 Kymera Therapeutics Inc Degradadores smarca e usos dos mesmos
EP4259144A4 (en) 2020-12-09 2025-08-20 Kymera Therapeutics Inc SMARCA DEGRADING AGENTS AND THEIR USES
WO2025196686A1 (en) * 2024-03-20 2025-09-25 Aurigene Oncology Limited Fused bicyclic compounds as smarca2 and/or smarca4 degraders
CN119874808B (zh) * 2025-01-02 2026-04-17 四川大学 一种靶向smarca蛋白降解的化合物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017518348A (ja) * 2014-06-20 2017-07-06 オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ Ｉｒａｋ４阻害剤としての置換インダゾール化合物
JP6815318B2 (ja) 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
MA41598A (fr) 2015-02-25 2018-01-02 Constellation Pharmaceuticals Inc Composés thérapeutiques de pyridazine et leurs utilisations
WO2017007612A1 (en) 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2017011371A1 (en) * 2015-07-10 2017-01-19 Arvinas, Inc Mdm2-based modulators of proteolysis and associated methods of use
EP3337476A4 (en) * 2015-08-19 2019-09-04 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
KR20190140438A (ko) * 2017-02-28 2019-12-19 에피자임, 인코포레이티드 암 치료를 위한 smarca2의 저해
US20190300521A1 (en) 2018-04-01 2019-10-03 Arvinas Operations, Inc. Brm targeting compounds and associated methods of use
US12371426B2 (en) 2018-04-26 2025-07-29 Aurigene Discovery Technologies Limited Pyridazine derivatives as SMARCA2/4 degraders
AU2021205326A1 (en) * 2020-01-10 2022-07-21 Amgen Inc. SMARCA2-VHL degraders

Also Published As

Publication number Publication date
EP4192835A4 (en) 2024-08-21
US20240018134A1 (en) 2024-01-18
EP4192835A1 (en) 2023-06-14
JP2023536504A (ja) 2023-08-25
WO2022029617A1 (en) 2022-02-10
CN116529250A (zh) 2023-08-01
MX2023001445A (es) 2023-05-08
BR112023002089A2 (pt) 2023-02-28
CA3188024A1 (en) 2022-02-10
AU2021320052A1 (en) 2023-03-23
US12570650B2 (en) 2026-03-10
IL300387A (en) 2023-04-01

Similar Documents

Publication Publication Date Title
KR20230061349A (ko) Smarca2 및/또는 smarca4 저하제로서 6-치환된 피리다진 화합물
US12371426B2 (en) Pyridazine derivatives as SMARCA2/4 degraders
CA3122317C (en) Isoindoline compound, and preparation method, pharmaceutical composition, and application of isoindoline compound
CN109912655B (zh) Alk蛋白降解剂及其抗肿瘤应用
AU2016272908A1 (en) Substituted heterocyclyl derivatives as CDK inhibitors
CN108137507A (zh) 基于mdm2的蛋白水解调节剂和相关的使用方法
WO2014134774A1 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
CN104370828A (zh) 用作raf激酶抑制剂的嘧啶衍生物
CN117143175A (zh) 靶向sos1蛋白泛素化调节的化合物及其制备方法和应用
WO2016020836A1 (en) Quinolone derivatives as antibacterials
AU2021339298A1 (en) Compounds for suppressing egfr mutant cancer and pharmaceutical use thereof
MX2014012991A (es) Derivado de benzamida.
KR20240012434A (ko) Kat6a 저해제로서의 융합된 이속사졸릴 화합물
JP2023513373A (ja) Ｐ２ｘ３修飾薬
WO2022037630A1 (zh) 四环类衍生物、其制备方法及其医药上的用途
WO2024214019A1 (en) Tetracyclic compounds as smarca2 and/or smarca4 degraders
MX2013002322A (es) Inhibidores de desacetilasas basados en hidroxamato.
AU2020274407B2 (en) Quinazoline-2,4-dione derivatives as PARP inhibitors
EA052684B1 (ru) 6​-замещенные пиридазиновые соединения в качестве деструкторов smarca2 и/или smarca4
JP2025506452A (ja) Ｓｍａｒｃａ２及び／又はｓｍａｒｃａ４分解剤としての３－置換ピリダジン化合物
RU2845145C1 (ru) Соединения для подавления рака с мутацией egfr и их фармацевтическое применение
WO2025094065A1 (en) Amino-substituted pyridazine compounds as smarca2 and/or smarca4 degraders
WO2025196686A1 (en) Fused bicyclic compounds as smarca2 and/or smarca4 degraders
KR20250170567A (ko) 치환된 아세틸렌 화합물 유도체 및 이의 약제학적 용도
WO2026036026A1 (en) (1h-indol-3-yl)(pyridin-2-yl)methanone derivatives as aryl hydrocarbon receptor (ahr) agonists for the treatment of inflammatory, autoimmune, metabolic or proliferative diseases

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902